Cargando…
Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin
BACKGROUND: Platinum compounds such as cisplatin and carboplatin are DNA crosslinking agents widely used for cancer chemotherapy. However, the effectiveness of platinum compounds is often tempered by the acquisition of cellular drug resistance. Until now, no pharmacological approach has successfully...
Autores principales: | Jacquemont, Céline, Simon, Julian A, D'Andrea, Alan D, Taniguchi, Toshiyasu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478989/ https://www.ncbi.nlm.nih.gov/pubmed/22537224 http://dx.doi.org/10.1186/1476-4598-11-26 |
Ejemplares similares
-
The Fanconi anemia pathway and ubiquitin
por: Jacquemont, Céline, et al.
Publicado: (2007) -
Planispine A Sensitized Cancer Cells to Cisplatin by Inhibiting the Fanconi Anemia Pathway
por: Singh, Thangjam Davis, et al.
Publicado: (2022) -
Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
por: Burkitt, Kyunghee, et al.
Publicado: (2008) -
Regulation of Rev1 by the Fanconi Anemia Core Complex
por: Kim, Hyungjin, et al.
Publicado: (2012) -
Mutated Fanconi anemia pathway in non-Fanconi anemia cancers
por: Shen, Yihang, et al.
Publicado: (2015)